CJC-1295 plus ipamorelin: hormone changes are not outcomes
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

CJC-1295 and ipamorelin approach growth-hormone signalling through different routes. That is a mechanism story, not yet proof of a useful combination. CJC-1295 is a growth-hormone-releasing-hormone analogue. Ipamorelin is a growth-hormone secretagogue. Their individual pharmacology explains why people discuss them together. Small human studies of long-acting CJC-1295 measured increases in growth hormone and IGF-one. They did not establish that adding ipamorelin improves health, strength or longevity. FDA has raised safety concerns about these substances. Also check the exact CJC formulation: products described as with or without DAC cannot inherit one another’s evidence.

END CARD
Evidence first. Educational only. Sources in description.

SOURCES
[1] Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults
https://pubmed.ncbi.nlm.nih.gov/16352683/
Primary randomized placebo-controlled human studies of long-acting CJC-1295

[2] Ipamorelin, the first selective growth hormone secretagogue
https://pubmed.ncbi.nlm.nih.gov/9849822/
Primary preclinical pharmacology

[3] FDA Pharmacy Compounding Advisory Committee briefing: CJC-1295-related substances
https://www.fda.gov/media/183819/download
US regulator technical assessment; distinct chemical forms and safety

[4] FDA: Certain bulk drug substances that may present significant safety risks
https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
US regulator; route-specific safety assessment, not a universal ban or approval list

EVIDENCE LIMITATIONS
Do not treat hormone elevation as a clinical benefit.
Do not transfer DAC-formulation duration or trial results to products labelled no-DAC.
No scheduling, stacking, dosing or body-composition promises.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
https://www.facebook.com/reel/3627640494062548/